NCT00506805View on ClinicalTrials.gov

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Cancer
Interventions
DRUG

SNX-5422

dose escalated, tablets every other day; undetermined duration until disease progression

Trial Locations (2)

37203

Pfizer Investigational Site, Nashville

85258

Pfizer Investigational Site, Scottsdale

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Serenex, Inc.

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Esanex Inc.

INDUSTRY